1997
DOI: 10.1016/s0306-4522(97)00277-7
|View full text |Cite
|
Sign up to set email alerts
|

Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

5
30
0

Year Published

1999
1999
2020
2020

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 59 publications
(35 citation statements)
references
References 58 publications
5
30
0
Order By: Relevance
“…30) In a variety of experimental models of PD, many NMDA receptor blockers have shown anticataleptic activity, including dizocilpine, phencyclidine, memantine. [31][32][33][34] In the present study, administration of amantadine, a DA releaser and a non-selective NMDA receptor antagonist, also alleviated catalepsy in LCa/Mg mice. This ameliorating effect might be due not only to amantadine's induction of DA release but also to its NMDA receptor antagonist properties.…”
Section: Discussionsupporting
confidence: 63%
“…30) In a variety of experimental models of PD, many NMDA receptor blockers have shown anticataleptic activity, including dizocilpine, phencyclidine, memantine. [31][32][33][34] In the present study, administration of amantadine, a DA releaser and a non-selective NMDA receptor antagonist, also alleviated catalepsy in LCa/Mg mice. This ameliorating effect might be due not only to amantadine's induction of DA release but also to its NMDA receptor antagonist properties.…”
Section: Discussionsupporting
confidence: 63%
“…However, downstream from the NAcc, the circuits activated by D-amphetamine and dizocilpine seem to diverge. Whereas the behavioral effects of D-amphetamine and other DA receptor agonists are mediated by reduction in the inhibitory tone of the NAcc-VP projections and an increase in VP functional output (Swerdlow et al, 1990), the behavioral actions of dizocilpine are independent of the VP and less well understood (Kretschmer and Koch, 1998;Mele et al, 1998;Kretschmer, 2000).…”
Section: Discussionmentioning
confidence: 99%
“…Systemic and focal administration of DA agonists in terminal areas, such as nucleus accumbens and striatum, enhances locomotor activity in laboratory animals, and these effects are blocked by selective lesion of these areas (Kelly et al 1975;Staton and Solomon 1984;Mele et al 1998). More recently, these areas have been related to cognitive functions, such as learning and memory (Taghzouti et al 1985;Annett et al 1989;Ploeger et al 1994;Floresco et al 1996Floresco et al , 1997Setlow 1997;Adriani et al 1998;Setlow and McGaugh 1998;Usiello et al 1998;Sargolini et al 1999).…”
Section: Introductionmentioning
confidence: 99%